BANGALORE, Sept 21 (Reuters) - Savient Pharma (SVNT.O) investors may be looking at windfall gains as regulatory approval for the firm’s gout drug could spark a bidding war valuing Savient at up to double its current stock price.
BANGALORE, Sept 21 (Reuters) - Savient Pharma (SVNT.O) investors may be looking at windfall gains as regulatory approval for the firm’s gout drug could spark a bidding war valuing Savient at up to double its current stock price.
